Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER plus breast cancer.

被引：0
|
作者：
Tonetti, Debra A.
Xiong, Rui
Zhao, Jiong
Gutgesell, Lauren
Dudek, Arkadiusz Z.
Thatcher, Gregory R.
机构：
[1] Univ Illinois, Chicago, IL USA
[2] TTC Oncol LLC, Edina, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e14090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14090
引用
收藏
页数：5
相关论文
共 37 条
  • [1] Lasofoxifene as a potential treatment for ER plus metastatic breast cancer.
    Laine, Muriel
    Fanning, Sean William
    Greene, Marianne
    Chang, Ya-fang
    Phung, Linda
    Tan, Tina T.
    Hiipakka, Richard
    Komm, Barry
    Greene, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Characterization of mutational processes in ER plus metastatic breast cancer.
    Buendia-Buendia, Jorge
    Cohen, Ofir
    Kim, Dewey
    Jain, Esha
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Safety of limited dose modifications for palbociclib associated neutropenia in ER plus metastatic breast cancer.
    Dominick, Anthony
    O'Dea, Anne
    Khan, Qamar J.
    Kimler, Bruce F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Lasofoxifene efficacy in a mammary intraductal ( MIND) xenograft model of ERα plus breast cancer.
    Laine, Muriel
    Greene, Marianne
    Chang, Ya-fang
    Phung, Linda
    Hiipakka, Richard
    Komm, Barry
    Greene, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Differential efficacy of antidepressants in the treatment of hormone mediated depression in patients with ER plus breast cancer.
    Kato, Martha M.
    Martinez, Constanza
    Currier, Maria
    Rubens, Muni B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER plus metastatic breast cancer.
    Wagle, Nikhil
    Helvie, Karla
    Lloyd, Maxwell R.
    Marini, Lori
    Waks, Adrienne Gropper
    Cohen, Ofir
    Oh, Coyin
    Sougnez, Carrie
    Oliver, Nelly
    Quartey, Qaren
    Rotem, Asaf
    Shah, Parin
    Lindeman, Neal Ian
    Krop, Ian E.
    Garraway, Levi A.
    Winer, Eric P.
    Lin, Nancy U.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] A Phase lb Dose Escalation Trial of R04929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER plus Metastatic Breast Cancer.
    Means-Powell, J. A.
    Minton, S. E.
    Mayer, I. A.
    Abramson, V. G.
    Ismail-Khan, R.
    Arteaga, C. L.
    Ayers, D. A.
    Sanders, M. S.
    Lush, R. M.
    Miele, L.
    CANCER RESEARCH, 2012, 72
  • [8] Efficacy and safety of everolimus for heavily pretreated patients with ER+/HER2-metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    Yamada, Mitsuhiro
    Suko, Kyoko
    Morioka, Junko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Selective human estrogen receptor partial agonist (ShERPAs) for treatment of tamoxifen-resistant ER plus breast cancer
    Delgado-Rivera, Loruhama M.
    CANCER RESEARCH, 2016, 76
  • [10] Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER plus metastatic breast cancer.
    Rosen, Ezra
    Sharma, Manish
    Berz, David
    Caswell-Jin, Jennifer Lee
    Spira, Alexander I.
    Fulgar, Georgina A.
    Densel, Mark
    Rana, Nawaid
    Sperry, Samuel
    Warner, Douglas
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
1234